News
Hemogenyx Pharma Plc - Director/PDMR Shareholding
Hemogenyx Pharmaceuticals Plc, the biotechnology company developing novel therapies to transform bone marrow, or blood stem cell, transplantation for the treatment of blood diseases, announces that on 9 April 2018 options to subscribe for 18,002,568 ordinary shares of £0.01 each in the Company were granted to Professor Sir Marc Feldmann, Chairman,...
Hemogenyx Pharmaceuticals Plc, the biotechnology company developing novel therapies to transform bone marrow, or blood stem cell, transplantation for the treatment of blood diseases, announces that on 9 April 2018 options to subscribe for 18,002,568 ordinary shares of £0.01 each in the Company were granted to Professor Sir Marc Feldmann, Chairman,...